Irritable bowel syndrome (IBS) is a common disorder characterized by recurrent abdominal pain and altered bowel habits, often accompanied by bloating.1-4 IBS is classified by its predominant bowel symptom: constipation (IBS-C), diarrhea (IBS-D), mixed type (IBS-M), or unclassified (IBS-U).1 Since the exact cause of IBS is unknown, the goal of treatment is symptom control. Some over-the-counter (OTC) products and prescription drugs for IBS are listed in Tables 1-4. The safety of these drugs during pregnancy and lactation is described in Table 5.
...- Comparison Chart: Safety of Drugs for IBS in Pregnancy and Lactation (online only)
- Figure 1: Treatments for Irritable Bowel Syndrome (IBS) in Adults (online only)
- Comparison Chart: Some Drugs for Abdominal Pain in Irritable Bowel Syndrome (IBS) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Constipation (IBS-C) (online only)
- Comparison Chart: Some Drugs for Irritable Bowel Syndrome with Diarrhea (IBS-D) (online only)
- Valeda Light Delivery System for Age-Related Macular Degeneration
- Emrosi — Low-Dose, Biphasic Oral Minocycline for Rosacea
- Dupilumab (Dupixent) for COPD
- Seladelpar (Livdelzi) for Primary Biliary Cholangitis
- Zenocutuzumab (Bizengri) for NSCLC and Pancreatic Adenocarcinoma
- Zanidatamab (Ziihera) for Biliary Tract Cancer (online only)
RELEASE
The FDA has required a new boxed warning in the label of the subcutaneously injected immunomodulatory drug glatiramer acetate (Copaxone, Glatopa, and generics) about a risk of anaphylaxis.1 Glatiramer has been used for years to treat relapsing forms of multiple sclerosis (MS).2
A review of data from the FDA Adverse Event Reporting System and published case reports identified 82 cases of anaphylaxis associated with use of glatiramer acetate that occurred between December 1996 and May 2024, including 51 requiring hospitalization and 6 that were fatal. Most cases occurred within 12 months after starting treatment with glatiramer (one was a sudden death after the first dose), but about 25% of the cases occurred >12 months after the drug was started. Anaphylaxis typically occurred within 1 hour after injection.1
Glatiramer acetate and interferon beta …